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Lack of 
realism 
Potholes, pitfalls and precipices 
Weak 
inputs 
Faulty 
technique 
Inadequate 
uncertainty 
handling 
Insufficient 
validation 
Poor 
reporting 
With Advanced Simulation  
Use all the data available to us 
Incorporate whatever new data become available, as 
they are generated 
Use individual’s values and examine the decision 
from his or her point of view.  
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Example: A Fib 
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5 x more likely 50% more deadly 
1.4 x more disabling 
systemic emboli 
AF: a vexing problem 
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5 x more likely 50% more deadly 
1.4 x more disabling 
systemic emboli 
67%↓ 
47% of time 
out of range 
<1/2 use it 
? 
Decision 1990’s Style 
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no AC 
warfarin 
Stroke 
Bleed 
Ps/W 
PB/W 
VS 
VB 
Nil 
1-PS-PB 
VN 
Predictors unknown: 
• stroke risk 
• bleeding risk 
• warfarin effect 
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6 x 
worse 
Personalized medicine: 
Decision 21st Century Style 
© J. Caro 
no AC 
warfarin 
Stroke 
Bleed 
Ps /W 
PB /W 
VS 
VB 
Nil 
1-PS-PB 
VN 
Predictors unknown: 
• stroke risk 
• bleeding risk 
• warfarin effect 
6 x 
worse 
CHA2DS2-VASc Condition Points 
C  Congestive heart failure 1 
H Hypertension: 1 
A2 Age ≥75 years 2 
D Diabetes Mellitus 1 
S2 Prior thromboembolism 2 
V Vascular disease 1 
A Age 65–74 years 1 
Sc Female 1 
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CHADS SCORE 
HAS-BLED Feature Score  
Hypertension (Systolic ≥ 160mmHg) 1 
Abnormal renal function 1 
Abnormal liver function 1 
Age ≥ 65 years 1 
Stroke in past 1 
Bleeding 1 
Labile INRs 1 
Taking other drugs as well 1 
Alcohol intake at same time 1 
VKORC1, CYP2C9 
i  
i  
Decision 21st Century Style 
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dabigatran 
rivaroxaban 
apixaban 
MI 
stop 
tmt 
don’t 
adhere 
VM 
Decision 21st Century Style 
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For people who have atrial fibrillation (AFib) not caused by a heart 
valve problem, “product” is the first and only once-a-day prescription 
blood thinner proven to reduce the risk of AFib-related stroke  
with no routine blood monitoring, no dietary restrictions, and no 
regular dosage adjustments. 
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AC – Anticoagulant 
AF –  Atrial  Fibrillation  
CRNM – Clinically Relevant   
Non-major Bleeding 
HS – Haemorrhagic stroke 
ICH –Intracranial  
Haemorrhage 
MI – Myocardial Infarction 
SE – Systemic Embolism 
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Limitations 
 This Markov model will not allow: 
– Modeling of stroke risk by CHADS2 or CHA2DS2-VASc 
– Detailed INR modeling 
• time spent in different INR ranges 
– Warfarin startup period + stabilization 
– Change in warfarin status (e.g., naïve to experienced to failure) 
– Updating CHADS2 scores after stroke event and age change 
– Event based adjustment of hazard rates (e.g., death) 
– Conditional event rates for subsequent events (e.g., stroke, bleed) 
– Modeling of treatment interruption, d/c or switching 
– Detailed modeling of resource use (e.g., treatment, MD visits, hospitalization and 
discharge) 
– Detailed modeling of hospital discharge 
– Capturing multiple events with competing risks 
 Can’t capture treatment-specific inputs (e.g., mRS distributions linked to AC) 
 Poor handling of complex competing risks 
 Cumbersome to run multiple scenarios x VKA status 
 No structural sensitivity analysis. 
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An attempt by industry – largely 
pharma –   
to justify the astronomical cost 
of their latest product! 
• Combine unrelated studies together in a model to paint the best case 
• Model population does not match the actual 
• Lack of objective evidence, thus, likely bias in mfr models 
• If direct costs still are not enough, add in indirect costs 
• Use quality of life measures to lay a guilt trip on Managed Care  
• Real world experience never meets model assumptions. 
Decision-Makers’ Opinions 
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Can’t We Do Better? 
© J. Caro 16 
Discrete Event Simulation 
Modeling technique that conceptualizes 
the course of individuals in terms of the 
events they experience and the effect 
these have on current and future health, 
medical resource use, and other 
components. 
DES for AF 
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Much More Detail 
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Limitations 
This Markov model will not allow: 
Modeling of stroke risk by CHADS2 or CHA2DS2-VASc 
Detailed INR modeling 
time spent in different INR ranges 
Warfarin startup period + stabilization 
Change in warfarin status (e.g., naïve to experienced to failure) 
Updating CHADS2 scores after stroke event and age change 
Event based adjustment of hazard rates (e.g., death) 
Conditional event rates for subsequent events (e.g., stroke, bleed) 
Modeling of treatment interruption, d/c or switching 
Detailed modeling of resource use (e.g., treatment, MD visits, 
hospitalization and discharge) 
Detailed modeling of hospital discharge 
Capturing multiple events with competing risks 
Can’t capture treatment-specific inputs (e.g., mRS distributions linked to AC) 
Poor handling of complex competing risks 
Cumbersome to run multiple scenarios by treatment status 
No  structural sensitivity analysis. 
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Strengths 
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Full  
              Easy   
Yes 
With Advanced Simulation  
Use all the data available to us 
Incorporate whatever new data become available, as 
they are generated 
Use individual’s values and examine the decision 
from his or her point of view 
Truly pursue personalized medicine – even in health 
economics!   
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